Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Editors Pick
    • 5 pharma giants under...

    5 pharma giants under NPPA lens for alleged overcharging

    Written by Ruby Khatun Khatun Published On 2018-01-10T13:49:13+05:30  |  Updated On 10 Jan 2018 1:49 PM IST
    5 pharma giants under NPPA lens for alleged overcharging

    NEW DELHI: Five pharma giants are under the scanner of NPPA for allegedly overcharging for a new Hepatitis C combination which they launched without waiting for price approval.


    Economic Times has recently reported that National Pharmaceutical Pricing Authority has sent show-cause notices to Hetero Labs, Cipla, Natco Pharma, Mylan Pharmaceuticals and Dr Reddy’s for overcharging the combination of sofosbuvir (400 mg) and velpatasvir (100 mg) used to treat the potentially fatal Hepatitis C virus.


    Natco, Mylan and Hetero have responded to the notices last week and the replies are under examination NPPA, reports ET


    In November 2017 NPPA had set the retail price of this drug sofosbuvir-velpatasvir combination at Rs 15,625 excluding GST with MRP set at Rs 17,500


    However, according to the minutes of the NPPA meeting, most brands of this combination were sold at Rs 18,500 while Hetero, Dr Reddy’s and Natco were among the first to launch the product in India in May 2017.






















































    CompanyBrandLaunchPrice for 28 tablets (Rs)
    Hetero LabsVelasof17 May17,619
    Cipla Ltd.Hepcvel17 May18,500
    Mylan PharmaMyHepAll17 July18,500
    Dr Reddy’s Ltd.Resof Total17 May18,500
    Natco PharmaVelpanat17 May18,500
    Abbott India Ltd.Velpaclear17 October17,500
    Zydus CadilaSoviHep V17 May18,500

    Source: ET

    Read also: Dr Reddys Laboratories launches generic hepatitis C drug in India


    Read also: Hetero gets DCGI nod for generic chronic hepatitis C drug

    NPPA is reported to have shown the desire to know how the companies arrived at the prices of their drug brands without due regulatory submissions and approvals. The notices specify recovery of overcharged amounts, penalties, a charge of 15% interest and prosecution measures as per the Essential Commodities Act.


    NPPA told ET, “Quantification of overcharging liability with interest and penalty to be calculated after examination of companies’ replies… a penalty not less than 100% of the principal amount shall be imposed in such cases.”


    Some companies who have received the notices said NPPA had delayed in setting the retail prices, although they had sought pricing price approval before launching the drug.


    Read also: Natco Pharma launches generic hepatitis C drug in India

    Speaking with ET, a Cipla spokesperson said, “We have received a preliminary notice from NPPA routinely asking for certain information on the product in question. We are in the process of collating such information to respond to NPPA.” He also added that no penalty has been imposed on the company.


    Seven brands of sofosbuvir-velpatasvir are available in India which is the generic versions of Gilead Sciences Inc’s Epclusa.


    Read also: Mylan launches tablets for treatment of Hepatitis C in India

    AbbottCadila HealthcareCiplaDr Reddy'sEpclusaGilead SciencesGoods and Services TaxHepatitis C combinationhepatitis C drugHetero LabsMylan PharmaceuticalsNatco pharmaNational Pharmaceutical Pricing AuthorityNPPAoverchargesPharma companiesprice approvalshowcause noticessofosbuvir 400 mgsofosbuvir-velpatasvir combinationunder scannervelpatasvir 100 mg
    Source : with inputs

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok